Maze Therapeutics, Inc. (MAZE) income statement
MAZENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$31.37−1.06 (-3.27%)
Close on Nov 20, 2026Market cap $1.74BP/E –Yield –
Maze Therapeutics, Inc. financial ratios
See a number that looks wrong?